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Abstract
Background: Metabolic syndrome (MetS), which includes a cluster of risk factors, is being
increasingly recognized as a new risk factor for cardiovascular disease. Heart rate turbulence
(HRT) is a Holter-based non-invasive method for detecting cardiac autonomic imbalance and
is an independent, powerful predictor of cardiac arrhythmias and sudden cardiac death in
different patient groups. This study evaluated the effect of MetS on HRT in non-diabetic
patients.
Methods: This study included 80 non-diabetic MetS subjects and 50 healthy subjects. All
130 subjects underwent a 24-h ambulatory Holter electrocardiogram recording. Two indices of
HRT were analyzed: turbulence onset (TO) and turbulence slope (TS). HRT values were
classified into 3 categories for risk stratification: 1) Category 0, TO and TS were normal;
2) Category 1, either TO or TS was abnormal; 3) Category 2, both TO and TS were abnormal.
Results: When we compared MetS rates in the HRT risk stratification groups, there were
significant differences for all groups as compared with the controls (Category 0 = MetS 28.8%,
n = 15, Control 71.2%, n = 37, p < 0.001; Category 1 = MetS 80.8%, n = 42, Control
19.2%, n = 10, p < 0.001; Category 2 = MetS 88.5%, n = 23, Control 11.5%, n = 3, p < 0.001).
In addition, TO and TS abnormalities were correlated with the number of MetS components
(r = 0.608, p < 0.001; r  = –0.388, p < 0.001, respectively).
Conclusions: To our knowledge, this is the first study to establish a relationship between
HRT and MetS. These findings suggest that MetS adversely affects HRT scores. In addition,
the number of MetS components is related to impaired HRT scores. (Cardiol J 2012; 19, 5: 507–512)
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Introduction
Heart rate turbulence (HRT) is a Holter-based
non-invasive method for detecting cardiac autono-
mic imbalance. This evaluation method is based on
the physiological sinus node response to a prema-
ture ventricular beat [1]. Cardiac autonomic im-
balance, manifested by impaired HRT, is a power-
ful risk factor for sudden cardiac death and mali-
gnant ventricular arrhythmia in patients with myo-
cardial infarction or congestive heart failure [2, 3].
Metabolic syndrome (MetS) consists of a group
of cardiovascular (CV) risk factors that includes
abdominal obesity, dyslipidemia, hypertension, and
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impaired glucose metabolism. Despite the ties to
dyslipidemia, insulin resistance, elevated blood
pressure, and abdominal obesity, the main patho-
physiological mechanism underlying the increased
CV risk is unclear. Autonomic dysfunction has also
been implicated in the pathophysiology of MetS [4].
MetS is associated with a 2-fold increase in CV out-
comes and a 1.5-fold increase in all-cause mortality
[5]. Cardiac autonomic dysfunction may contribute
to the pathophysiological process of MetS with re-
spect to CV outcomes. We hypothesized that the
increased CV risk of MetS was related to cardiac
autonomic dysfunction.
This study evaluated the relationship between
MetS and cardiac autonomic dysfunction as detected
by HRT. Since diabetic neuropathy and autonomic
dysfunction in diabetic patients may affect HRT
analysis, the study evaluated non-diabetic patients.
Methods
Patients
Eighty non-diabetic patients with MetS and
50 healthy age and sex matched subjects from Saita-
ma Medical University Hospital Cardiology Depart-
ment outpatient clinics were enrolled in this study.
The control group consisted of 50 healthy persons,
whose Holter recordings demonstrated ventricular
premature beats (VPB) suitable (> 6/day) for HRT
analysis. Subjects were excluded if they had
rhythms other than sinus as atrial fibrillation or flut-
ter, diabetes mellitus, coronary artery disease, an
implanted permanent pacemaker, drug use that may
influence HRT such as; beta blockers, Ca++ chan-
nel blockers, Group I and IV antiarrhythmics, ACE
inhibitors, etc., inadequate VPB to measure HRT,
and refusal to provide informed consent for the
study.  The study was approved by the local ethic
committee and all subjects gave written informed
consent.
Anthropometric analysis
Body weight and height was measured with the
patient in light clothes without shoes to the near-
est 0.5 kg and 0.5 cm. Waist circumference was
measured horizontally in quiet expiration, halfway
between the lower rib and the iliac crest. Body mass
index was calculated as weight [kg] divided by
height squared [m].
Metabolic syndrome definition
The presence of MetS was established accord-
ing to National cholesterol education program-adult
treatment panel III criteria, using the Asian Pacific
World Health Organization modification [1]. MetS
was diagnosed if more than 3 of the following com-
ponents are present; a) abdominal obesity: waist
circumference > 90 cm in men and > 80 cm in
women; b) triglyceride level 1.7 mmol/L or greater;
c) HDL-cholesterol less than or equal to 1.0 mmol/L
in men and less than or equal to 1.3 mmol/L in women;
d) blood pressure: ≥ 130/85 mm Hg; e) fasting glu-
cose level of 6.1 mmol/L or greater.
Holter monitoring and HRT analysis
The 24-h Holter recordings of all patients were
analyzed to obtain the HRT parameters of turbu-
lence onset (TO) and turbulence slope (TS). Re-
cordings were performed with a GE Marquette
SEER system digitizing at 125 samples per second
(GE Marquette, Milwaukee, WI). QRS detection,
morphology classification (normal, aberrant, prema-
ture aberrant) and measurement of the RR interval
were automatically performed by the system. All
Holter files were reviewed and manually correct-
ed. HRT analysis was performed on sequences of
sinus RR intervals after VPB. The evaluated sinus
rhythm immediately before and after the VPB was
free from any arrhythmia or other artifacts. The
HRT after a VPB comprises two parameters: TO,
which represents the initial acceleration (shorten-
ing of R-R intervals); and TS, which represents the
subsequent deceleration (prolongation of R-R inter-
vals) [2]. In mathematical terms, TO (%) (normal
< 0)  is the difference between the sum of the first
two R-R intervals after the compensatory pause
following a VPB and the sum of the last two R-R
intervals preceding the VPB, divided by the sum of
the last two R-R intervals preceding the VPB. The
TS (normal > 2.5 ms/R-R interval number) were
accepted as the steepest slope of a regression line
over any sequence of five consecutive R-R intervals.
The average of HRT values measured for all con-
venient VPBs was accepted as the final HRT value
to characterize the patient [3, 4]. For the risk stra-
tification HRT values [5] are classified into 3 cate-
gories: 1) Category 0: TO and TS are normal;
2) Category 1: one of TO or TS is abnormal; 3) Cate-
gory 2: both TO and TS are abnormal.
Statistical analysis
All statistical analyses were performed using
the SPSS software package 15.0 (SPSS Inc, Chica-
go, IL, USA). Data are presented as frequencies and
percentages for categorical variables and mean ± SD
for continuous variables. Differences between
2 groups were assessed using the c2 and unpaired
t-tests. Because total onset, total slope and MetS
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values were not normally distributed, between-
-group differences were assessed by the one-way
ANOVA. Pearson’s and Spearman’s correlation co-
efficients were used to test the relationship be-
tween the TO, TS and MetS factors. Linear logis-
tic regression analysis was performed to identify the
independent determinants of MetS (including sys-
tolic blood pressure, diastolic blood pressure, waist
circumference, triglyceride levels, HDL-cholesterol
levels, fasting glucose, TO and TS). A value of p < 0.05
was considered statistically significant.
Results
Eighty MetS patients (38 [47.5%] male, 42
[52.5%] female) and 50 healthy control (24 [48.0%]
male, 26 [52.0%] female) were included in this
study. MetS group clinical characteristics were
shown in Table 1. When we compare the MetS rates
with respect to the HRT risk stratification groups,
there were significant differences for all category
(Category 0 = MetS 28.8%, n: 15, Control 71.2%,
n: 37, p < 0.001; Category 1 = MetS 80.8%, n: 42,
Control 19.2%, n: 10, p < 0.001; Category 2 = MetS
88.5%, n: 23, Control 11.5%, n: 3, p < 0.001, re-
spectively) (Fig. 1). TO and TS values of MetS
group were significantly different compared with
the control group (0.36 ± 1.40 vs. –0.49 ± 1.03,
p < 0.001; 2.44 ± 1.37 vs. 1.92 ± 0.70, p = 0.012,
respectively).
In the subgroup analysis of MetS group, pa-
tients were compared in number of MetS compo-
nents, there were statistically significant difference
in TO and TS values (Table 2). Also a strong posi-
tive correlation between the number of MetS com-
Table 1. Baseline characteristics of the two study groups.
MetS group (n = 80) Control group (n = 50) P
Age [years] 42.1 ± 5.0 41.0 ± 5.1 0.351
Gender (male/female) 38/42 24/26 0.647
Body mass index [kg/m2] 28.7 ± 4.6 28.3 ± 4.9 0.693
Waist circumference [cm]:
Men 103.1 ± 16.8 94.8 ± 11.7 0.041
Women 107.2 ± 12.7 95.5 ± 12.4 0.032
Fasting plasma glucose [mg/dL] 101.7 ± 21.2 94.3 ± 11.4 0.306
Triglyceride [mg/dL] 161.6 ± 65.4 105.0 ± 44.2 0.028
HDL-cholesterol [mg/dL] 41 ± 8 46 ± 12 0.038
Current smoking 42 (52.5%) 13 (26.0%) 0.012
Systolic blood pressure [mm Hg] 132.5 ± 8.5 123.3 ± 6.4 0.009
Diastolic blood pressure [mm Hg] 89.2 ± 8.7 72.4 ± 6.2 0.011
Table 2. Subgroup analysis of metabolic syndrome (MetS) group in total onset and total slope.
MetS (mc: 3) MetS (mc: 4) MetS (mc: 5) P
Total onset –0.5 ± 1.2 0.7 ± 0.9 1.6 ± 1.1 < 0.001
Total slope 3.2 ± 0.5 2.0 ± 1.3 1.4 ± 1.2 < 0.001
mc — number of the metabolic syndrome components
Figure 1. Metabolic syndrome (MetS) rates with respect
to the heart rate turbulence risk stratification group.
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ponents and TO, a moderate negative correlation
between the number of MetS components and TS
were detected (r = 0.608, p < 0.001, r = –0.388,
p < 0.001) (Fig. 2). In linear logistic regression anal-
ysis (including systolic blood pressure, diastolic
blood pressure, waist circumference, triglyceride
levels, HDL-cholesterol, fasting glucose, TO and
TS) waist circumference, systolic blood pressure,
triglyceride levels and TO was found to be signifi-
cant and independent predictors of MetS (Table 3).
Patients who have 5 components of MetS were
more likely than the 3 components MetS patients
to have Category 2 (adjusted odds ratio [OR] = 1.4;
95% confidence interval [CI] = 1.03–2.03; p = 0.04).
Patients who have 4 criteria of MetS were not more
likely than 3 criteria MetS group to have Category
1 turbulence (adjusted OR = 1.2; 95% CI = 0.8–
–1.9; p = 0.29) but were more likely to have Catego-
ry 2 turbulence (adjusted OR = 1.8; 95% CI = 1.1–
–3.0; p = 0.03). All group of MetS were more likely
than the Control group to have Category 1 or Cate-
gory 2 turbulence (respectively, 2.3; 95% CI = 1.1–
–4.9; p = 0.03; 1.4; 95% CI = 1.03–2.03; p = 0.04;
1.3; 95% CI = 1.1–1.9; p = 0.038).
A statistically significant difference between
the two groups was found in terms of VPB number
detected by 24-h Holter (MetS: 36.73 ± 28.81;
Control: 10.58 ± 10.31; p < 0.001). A statistically
strong significant positive correlation was found
between the number of VPB and number of MetS
components (r = 0.695, p < 0.001). When 3 groups
according to the number of MetS components were
formed, a statistically significant difference was
found in terms of the VPB number among the
groups (12.85 ± 4.59; 40.60 ± 34.93; 80.34 ± 67.80;
p < 0.001, respectively).
Discussion
The principal findings of our study were that
1) MetS patients were more likely to have abnor-
mal HRT than the control group, 2) the TO and TS
were significantly different between the MetS and
Control groups, 3) there were significant differenc-
es in TO and TS in the MetS subgroup analysis
when comparing the number of MetS components,
4) TO was a significant, independent predictor of
MetS presence, and 5) there was a significant posi-
tive correlation between the numbers of VPBs and
MetS components.
Figure 2. Correlation between metabolic syndrome (MetS) criteria number and heart rate turbulence parameters.
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Table 3. Linear logistic regression analysis of
variables associated with metabolic syndrome.
Beta 95% CI P
Fasting glucose 0.285 0.001–0.002 0.250
Waist circumference 0.372 0.006–0.014 < 0.001
Triglyceride 0.290 0.001–0.002 0.005
HDL-cholesterol 0.033 –0.010–0.007 0.394
Systolic BP 0.321 0.004–0.018 0.002
Diastolic BP 0.127 –0.003–0.014 0.184
Total onset 0.201 0.002–0.012 0.009
Total slope 0.031 –0.002–0.001 0.588
CI — confidence interval; BP — blood pressure
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The heart is highly innervated by vagal and
sympathetic fibers and is very sensitive to autonomic
influences [6]. The autonomic nervous system re-
sponds to all changes sensed by baroreceptors and
chemoreceptors to maintain CV homeostasis [2].
Studies have shown that cardiac autonomic dysfunc-
tion plays an essential role in the development of
CV disease in MetS patients [7, 8]. HRT is an im-
portant parameter for evaluating cardiac autonomic
functions. A blunted HRT reflects cardiac autono-
mic dysfunction, especially reduced baroreflex sen-
sitivity [5]. HRT is reduced not only following
myocardial infarction, but also in patients with
a variety of diseases affecting the heart, congestive
heart failure, and possibly diabetes. Further, HRT
may provide clinically useful risk stratification in-
formation [9–11].
Many studies have suggested that MetS is
a powerful predictor of the risk of developing CV dis-
ease [12]. In a meta-analysis of 21 studies, CV dis-
ease, coronary heart disease, stroke, and mortality
were more prevalent in patients with MetS than in
patients without it [13]. We found a similar result in
that MetS patients demonstrated abnormal HRT
more often than the control group. In addition, the
MetS group showed abnormal TO and TS values as
compared with the control group. We believe that the
relationship between MetS and CV disease deve-
lopment is related to cardiac autonomic dysfunction.
The number of MetS components is associated
with CV mortality and morbidity [7, 8]. Protorov and
Glukhovsky [14] showed a significant correlation
between arrhythmias and the number of MetS com-
ponents. Similarly, we found that the number of
MetS components was positively correlated with
TO and negatively correlated with TS. Therefore,
the number of MetS components, including abdom-
inal obesity, low HDL-cholesterol levels, hypertri-
glyceridemia, high blood pressure, and high fasting
glucose, is an important factor for increased CV risk.
Cardiac autonomic dysfunction in patients with
MetS can be evaluated using different parameters,
such as heart rate variability (and heart rate recov-
ery. However, HRT has not been used in this situ-
ation. Studies have established a relationship be-
tween cardiac autonomic dysfunction and MetS.
One study revealed that heart rate recovery is sig-
nificantly impaired in young adult males with MetS
[7]. Stein et al. [15] found that reduced heart rate
variability was a valuable marker of cardiac auto-
nomic dysfunction, and was associated with MetS,
independent of fasting glucose levels. We also de-
termined that HRT was impaired in MetS patients
without diabetes mellitus as compared with healthy
subjects. To our knowledge, this is the first study
establishing a relationship between HRT and MetS.
Another important risk factor for CV mortality
is VPBs [16]. Premature ventricular contractions
leading to ventricular tachycardia, which can in turn
degenerate into ventricular fibrillation, is a common
mechanism underlying sudden cardiac death. Cli-
nically, a decrease in premature ventricular contrac-
tions would improve ventricular function and sud-
den cardiac death [17]. Provotorov and Glukhovsky
[18] found that patients with MetS more frequent-
ly had polymorphic VPBs associated with an ele-
vated mean heart rate. Similarly, we found a signi-
ficant difference between the MetS and Control
groups in terms of VPBs and a significant positive
correlation between the numbers of VPBs and MetS
components.
Limitations of the study
The main limitation of our study was the small
sample size. Since a small sample size results in low
statistical power for equivalency testing, negative
results may be simply due to chance. In addition,
we did not examine the impact of circadian varia-
tion. Diurnal fluctuations in autonomic tone suggest
one value for HRT in 24 h. This may also influence
the results.
Conclusions
In conclusion, our results revealed that HRT
is significantly impaired in MetS patients without
diabetes mellitus. HRT is a significant predictor of
cardiac autonomic dysfunction and it is useful to
identify MetS patients without diabetes mellitus
who have potentially increased CV risk.
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